Skip to content

Nasdaq · CIK 0002022626

UPB Upstream Bio, Inc.

Insider trading from SEC Form 4. Last filing Feb 7, 2025. Close $4.70 on Oct 9, 2026, +3% from the 52-week low and -86% from the high.

Last 90 days

Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
12
with a Form 4 at this company

Price and insider trades, last year

UPB, daily close, last year. insider buy insider sellDot size follows the dollar value (largest $20M).

Signals

Open-market buys and sells at Upstream Bio, Inc., scored.

ScoreSideInsiderValueSharesHoldings changePrice contextFiled
40Moderatebuy 310b5-1AI Upstream LLC
owner
$20M1,175,000--
65Notablebuy 3Chimovits Erez
director, owner
$14M825,000+85%-
65Notablebuy 3ORBIMED ADVISORS LLC
director, owner
$14M825,000+85%-

Transactions

The last 33 rows filed, every code.

DateInsiderTransactionSharesPriceValueHoldings afterFiled
Feb 6, 2025Deykin Aaron
Chief Medical Officer
AGrant or award
Stock Option (Right to Buy)derivative
+165,000$0.00$0165,000Feb 7, 2025
Feb 6, 2025GRAY MICHAEL
CFO and COO
AGrant or award
Stock Option (Right to Buy)derivative
+195,000$0.00$0195,000Feb 7, 2025
Feb 6, 2025Ambrose Allison
General Counsel
AGrant or award
Stock Option (Right to Buy)derivative
+25,000$0.00$025,000Feb 7, 2025
Dec 16, 2024Ambrose Allison
General Counsel
AGrant or award
Stock Option (Right to Buy)derivative
+100,000$0.00$0100,000Dec 17, 2024
Oct 15, 2024AI Upstream LLC
owner
POpen-market purchase
Common Stock10b5-1
+1,175,000$17.00$20M1,175,000Oct 17, 2024
Oct 15, 2024Chimovits Erez
director, owner
CConversion
Common Stockindirect: See Footnote
+721,956--973,716Oct 17, 2024
Oct 15, 2024ORBIMED ADVISORS LLC
director, owner
CConversion
Common Stockindirect: See Footnote
+721,956--973,716Oct 17, 2024
Oct 15, 2024AI Upstream LLC
owner
CConversion
Common Stock10b5-1
+3,147,000--4,322,000Oct 17, 2024
Oct 15, 2024Chimovits Erez
director, owner
POpen-market purchase
Common Stockindirect: See Footnote
+165,000$17.00$2.8M1,138,716Oct 17, 2024
Oct 15, 2024ORBIMED ADVISORS LLC
director, owner
POpen-market purchase
Common Stockindirect: See Footnote
+165,000$17.00$2.8M1,138,716Oct 17, 2024
Oct 15, 2024AI Upstream LLC
owner
CConversion
Common Stock10b5-1
+1,172,410--5,494,410Oct 17, 2024
Oct 15, 2024ORBIMED ADVISORS LLC
director, owner
CConversion
Common Stockindirect: See Footnote
+2,887,833--3,894,873Oct 17, 2024
Oct 15, 2024Chimovits Erez
director, owner
CConversion
Common Stockindirect: See Footnote
+2,887,833--3,894,873Oct 17, 2024
Oct 15, 2024Chimovits Erez
director, owner
POpen-market purchase
Common Stockindirect: See Footnote
+660,000$17.00$11M4,554,873Oct 17, 2024
Oct 15, 2024ORBIMED ADVISORS LLC
director, owner
POpen-market purchase
Common Stockindirect: See Footnote
+660,000$17.00$11M4,554,873Oct 17, 2024
Oct 15, 2024AI Upstream LLC
owner
CConversion
Series A Convertible Preferred Stockderivative10b5-1
-3,147,000--0Oct 17, 2024
Oct 15, 2024Chimovits Erez
director, owner
CConversion
Series A redeemable convertible preferred stockderivativeindirect: See Footnote
-524,500--0Oct 17, 2024
Oct 15, 2024AI Upstream LLC
owner
CConversion
Series B Convertible Preferred Stockderivative10b5-1
-1,172,410--0Oct 17, 2024
Oct 15, 2024ORBIMED ADVISORS LLC
director, owner
CConversion
Series A redeemable convertible preferred stockderivativeindirect: See Footnote
-524,500--0Oct 17, 2024
Oct 15, 2024Chimovits Erez
director, owner
CConversion
Series A redeemable convertible preferred stockderivativeindirect: See Footnote
-2,098,000--0Oct 17, 2024
Oct 15, 2024ORBIMED ADVISORS LLC
director, owner
CConversion
Series A redeemable convertible preferred stockderivativeindirect: See Footnote
-2,098,000--0Oct 17, 2024
Oct 15, 2024Chimovits Erez
director, owner
CConversion
Series B redeemable convertible preferred stockderivativeindirect: See Footnote
-197,456--0Oct 17, 2024
Oct 15, 2024ORBIMED ADVISORS LLC
director, owner
CConversion
Series B redeemable convertible preferred stockderivativeindirect: See Footnote
-197,456--0Oct 17, 2024
Oct 15, 2024Chimovits Erez
director, owner
CConversion
Series B redeemable convertible preferred stockderivativeindirect: See Footnote
-789,833--0Oct 17, 2024
Oct 15, 2024ORBIMED ADVISORS LLC
director, owner
CConversion
Series B redeemable convertible preferred stockderivativeindirect: See Footnote
-789,833--0Oct 17, 2024
Oct 15, 2024Wellington Biomedical Innovation Master Investors (Cayman) II L.P.
owner
CConversion
Common Stock
+894,733--894,733Oct 15, 2024
Oct 10, 2024Beckman Daniella
director
AGrant or award
Stock Option (Right to Buy)derivative
+34,681$0.00$034,681Oct 15, 2024
Oct 10, 2024Chimovits Erez
director
AGrant or award
Stock Option (Right to Buy)derivative
+17,096$0.00$017,096Oct 15, 2024
Oct 10, 2024Fleming Harold Edward
director
AGrant or award
Stock Option (Right to Buy)derivative
+17,096$0.00$017,096Oct 15, 2024
Oct 10, 2024Ratcliffe Liam
director
AGrant or award
Stock Option (Right to Buy)derivative
+17,096$0.00$017,096Oct 15, 2024
Oct 10, 2024Renaud Ronald C JR
director
AGrant or award
Stock Option (Right to Buy)derivative
+17,096$0.00$017,096Oct 15, 2024
Oct 10, 2024Ruddy Marcella K.
director
AGrant or award
Stock Option (Right to Buy)derivative
+17,096$0.00$017,096Oct 15, 2024
Oct 15, 2024Wellington Biomedical Innovation Master Investors (Cayman) II L.P.
owner
CConversion
Series B redeemable convertible preferred stockderivative
-852,940$0.00$00Oct 15, 2024

Insiders

Everyone who has filed a Form 4 here.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

UPB insider trading: Upstream Bio, Inc. | InsiderTell